Current Anti-Amyloid-β Therapy for Alzheimer’s Disease Treatment: From Clinical Research to Nanomedicine
Zixuan Zhao,1,2,* Yun Liu,1,2,* Shirong Ruan,1,2 Yixuan Hu1,2 1Department of Neurosurgery, The Translational Research Institute for Neurological Disorders, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College), Wuhu, 241000, People’s Re...
Main Authors: | Zhao Z, Liu Y, Ruan S, Hu Y |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2023-12-01
|
Series: | International Journal of Nanomedicine |
Subjects: | |
Online Access: | https://www.dovepress.com/current-anti-amyloid--therapy-for-alzheimers-disease-treatment-from-cl-peer-reviewed-fulltext-article-IJN |
Similar Items
-
Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s Disease: A Focus on Aducanumab and Lecanemab
by: Mingchao Shi, et al.
Published: (2022-04-01) -
The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer’s disease: a systematic review and meta-analysis of randomized controlled trials
by: Wenxue Wu, et al.
Published: (2023-11-01) -
An amyloid-β protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease
by: Anna Lord, et al.
Published: (2009-12-01) -
Oxidative Stress and Beta Amyloid in Alzheimer’s Disease. Which Comes First: The Chicken or the Egg?
by: Elena Tamagno, et al.
Published: (2021-09-01) -
Immunotherapy for the treatment of Alzheimer's disease: amyloid-β or tau, which is the right target?
by: Castillo-Carranza DL, et al.
Published: (2013-12-01)